Abstract:Objective To determine the accurate age-adjusted incidence of prostate small cell carcinoma (SCC), update the clinical and pathological characteristics, as well as survival data of prostate SCC from Surveillance, Epidemiology, and End Results (SEER) datasets. Methods A total of 260 patients with prostate SCC were selected from the SEER database of the National Cancer Institute between 2004 and 2015. Age-adjusted incidence (AAI) rates, the observed and relative survival rates were evaluated over time by the SEER*Stat Software version 8.3.5. Overall survival (OS) rates that stratified by summary stage and treatment effects were evaluated by Kaplan-Meier method. The significant differences were assessed in a log-rank test. Univariate and multivariate cox hazard regression analysis were performed to determine independent predictors of OS. Results The incidence of prostate SCC has increased over time. The average age of prostate SCC patients was 70.25 years. More than 90% of tumors were poorly differentiated or undifferentiated. The majority of prostate SCC (77.7%) was at stage IV. 49% of patients had lymph node metastases and 68% of patients presented distant metastases (Compared with 60.5% of patients with distant metastases between 1973-2003). Interestingly only 23.5% patients had high level PSA (>10 ng/mL). 58.8% of patients underwent chemotherapy, 25.4% of patients were treated by surgery, and 31.9% of patients were treated by radiotherapy. The observed survival rates of 1-year, 2-year, and 5-year were 42.1%, 22.1%, and 12.5%, respectively (Compared with 47.9%, 27.5%, and 14.3%, respectively, between 1973 and 2003). Chemotherapy prolonged the OS of patients with regional (distant) metastases from 3 months (2 months) to 12 months (9 months). Multivariate cox regression analysis showed age, race, and stage were independent prognostic factors for prostate SCC patients. Conclusion Prostate SCC is a highly malignant cancer and our analysis of recent data has shown its incidence is increasing. Incidence rate of metastatic prostate SCC has increased and the survival rates have worsened in recent years. However, chemotherapy shows some survival benefit for prostate SCC patients with regional and distant metastasis over other treatment methods. Further work is needed to understand the reason prognosis of this type prostate cancer is worsening.

[Adenocarcinoma of the prostate in patients under 50 years of age: analysis of 10 cases].

Clinical Analysis of Prostate Cancer in Young Men under 50 Years

Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations

[Clinical and pathological characteristics of prostate cancer patients younger than 55 years old].

Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study

Prostate Biopsy Results and Clinicopathological Characteristics of the 55 Years or Younger Patients

Clinicopathologic analysis of prostate biopsy in men younger than 50 years of age with prostate-specific antigen 4-10 μg/L

[Clinicopathologic Characteristics and Prognosis of Early Onset Prostate Cancer].

Demographics, Risk Factors and Survival Analysis of Lung Cancer in Young Adults (&lt;30 Years) in China-A Retrospective Cohort Study

[Age and Pathological Features of 481 Prostate Cancer Patients].

Prognosis of Prostate Cancer and Bone Metastasis Pattern of Patients: a SEER-based Study and a Local Hospital Based Study from China

Prostate Cancer in Asia: A Collaborative Report

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 Ng/ml.

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

Unfavourable Clinicopathologic Features and Low Response Rate to Systemic Adjuvant Therapy: Results with Regard to Poor Survival in Young Chinese Breast Cancer Patients

Analysis of the Molecular and Clinicopathologic Features of Surgically Resected Lung Adenocarcinoma in Patients under 40 Years Old.

Pathological Features of Localized Prostate Cancer in China: a Contemporary Analysis of Radical Prostatectomy Specimens.

Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤60 years: real-world data from a single urological center over a 10-year period

Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending Upon the Patient Age?

Reduced Survival of Young Patients under 55 Years with Metastatic Prostate Cancer: a Population-Based Study

Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts